Sienna Biopharmaceuticals Inc. on Monday filed paperwork with the Securities and Exchange Commission for an initial public offering to raise up to $74.8 million. The Westlake Village startup develops clinical stage topical treatments used for skin conditions such as psoriasis, as well as laser treatments for acne and hair removal. The company acquired its lead products through an acquisition of U.K.-based pharmaceutical company, Creabilis, last December. In April the company completed its Series B financing round, raising $40 million. Most of Sienna’s executive team came from another Westlake Village biotech Kythera, which was acquired by Allergen in 2015 for $2.1 billion.
